Enveric Biosciences has entered a non-binding term sheet with MindBio Therapeutics for the out-licensing of a class of psilocin prodrugs (NPP) aimed at treating mental health disorders. The NPP molecules…
Read More
Enveric Biosciences, Inc. (NASDAQ: ENVB) told investors it has signed a non-binding term sheet to out-license a class of Novel Psilocin Prodrugs (NPP) to Vancouver, BC-based MindBio Therapeutics (CNSX: MBIO),…
Read More
In a groundbreaking move within the pharmaceutical industry, Enveric Biosciences (NASDAQ: ENVB) a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety,…
Read More
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today…
Read More
Psychedelics biotech firm, Enveric Biosciences has signed a non-binding term sheet to out-license a class of Novel Psilocin Prodrugs (NPP) to Vancouver, British Columbia-based biopharma company MindBio Therapeutics Corp CSE:…
Read More
Enveric Biosciences, a notable player in biotechnological innovations, has recently announced a significant licensing agreement that might change the landscape of cancer treatment. According to a recent press release from…
Read More
Enveric Biosciences, a Nasdaq-listed psychedelics biotech firm, has entered into a non-binding term sheet with an undisclosed biotech company (licensee) for an exclusive license to two patented methods aimed at…
Read More
Mental health disorders have long been a significant global challenge, affecting millions of individuals and placing an immense burden on healthcare systems worldwide. Despite substantial investments in research and development,…
Read More
In a significant stride toward transforming the landscape of joint disease treatment, Enveric Biosciences has inked two non-binding term sheets with a yet undisclosed biotechnology company. This promising collaboration is…
Read More
Once stigmatized, mental health conditions like anxiety, depression, schizophrenia, and post-traumatic stress disorder are now gaining recognition in society thanks to years of research that have enabled us to identify…
Read More
